Emerging patterns of kidney cancer in young adults: where do we stand?

Renal cell carcinoma (RCC) is traditionally considered a disease of older adults; however, its incidence among young individuals is steadily increasing. Despite this epidemiologic shift, early-onset RCC remains poorly characterized and is still largely managed according to evidence derived from older populations. Available retrospective series suggest that younger patients more frequently present with localized disease and experience improved cancer-specific and overall survival compared with older counterparts. Nevertheless, they also exhibit greater histologic and molecular heterogeneity, with an overrepresentation of rare and genetically defined subtypes, including TFE3-rearranged and TFEB-altered RCC, fumarate hydratase-deficient RCC, succinate dehydrogenase-deficient RCC and SMARCB1-deficient renal medullary carcinoma. These entities are frequently associated with hereditary cancer syndromes and distinct metabolic patterns. In parallel, von Hippel-Lindau-related RCC and the development of HIF-2α inhibitors such as belzutifan illustrate how targeting lineage-specific pathways can modify the natural history of early-onset disease and reduce the burden of repeated local interventions. Emerging evidence also suggests that immune checkpoint inhibitor (ICI)-based combinations, particularly those incorporating VEGFR-targeted tyrosine kinase inhibitors, may provide clinically meaningful activity across several rare RCC subtypes, whereas outcomes with monotherapy remain variable. This evidence remains promising but preliminary and is not specific to young adults. A deeper molecular characterization of early-onset RCC may enable earlier detection and more accurate risk stratification, ultimately guiding treatment selection. Dedicated prospective studies are urgently needed to define age-specific management strategies, including surveillance protocols, genetic counseling, and personalized therapeutic approaches for young patients with RCC.